【BCIC Ecosystem】
Leveragen Joins Forces with Global Pharma Giant Daiichi Sankyo to Accelerate Next-Generation Antibody Drug Development
Leveragen, the Boston-based biotechnology company, has announced a strategic collaboration agreement with global pharmaceutical leader Daiichi Sankyo. As the recipient of the Innovation Award at the 2024 Biomedical Pitch Competition, Leveragen has once again won recognition from a top-tier international pharma with its hardcore technical strength.
From Pitch Competition Innovation Award to Multinational Partner
This collaboration marks the entry of Leveragen's next-generation in vivo antibody discovery platform into the view of leading global industry players. The two parties will jointly explore innovative pathways to support Daiichi Sankyo's advanced biologics R&D across multiple therapeutic areas.
Key Highlights — Closed-loop Ecosystem, Hardcore Validation
Leveragen's leading genetic engineering technology helped it stand out in the 2024 competition. The Daiichi Sankyo partnership reaffirms the precision of the competition's judging panel in identifying high-potential projects.
A Powerhouse Alliance
As a global leader in ADC (antibody-drug conjugates) and biologics, Daiichi Sankyo's choice of the Leveragen platform reflects high confidence in Leveragen's ability to generate high-quality antibody candidates within physiological immune environments.
Technology-Powered
Leveragen's precise genetically engineered mouse models can significantly improve the efficiency and precision of early research and preclinical development.
Leveragen Founder & CEO Dr. Weisheng Chen stated:
"We are deeply honored to collaborate with a global leader of Daiichi Sankyo's scientific depth. This partnership reflects strong industry interest in next-generation in vivo discovery platforms and lays a solid foundation for jointly developing breakthrough biologics."
Rooted in Boston with global reach, Leveragen continues to apply its frontier technology in oncology, immunology, neuroscience and other key areas. We look forward to seeing more excellent competition projects like Leveragen flourish on the innovation soil of Boston, jointly advancing global life sciences.
